Viktor Grünwald, MD, PhD, University Hospital Essen, details the CLEAR study as well as the subgroup analysis on the efficacy of lenvatinib plus pembrolizumab for patients with aRCC. He also comments on how the available combination approaches compare for frontline aRCC, and whether there are discernable differences that separate any combination as superior in this setting.
CLEAR and Navigating the Frontline Combination Approaches for Advanced RCC
By Viktor Grünwald, MD, PhD - Last Updated: May 1, 2024Related Posts
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
The combination therapy provided similar survival rates and toxicity in an older patient population.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.